Hollister Biosciences Reports 300% YoY Increase In Cash Balance As Stock Plunges After Q3 Earnings
Hollister Biosciences Reports 300% YoY Increase In Cash Balance As Stock Plunges After Q3 Earnings
Hollister Biosciences Inc. (CSE:HOLL) (OTC:HSTRF) (FRANKFURT: HOB) announced its financial results Monday for the third quarter of fiscal 2021 ended Sept. 30.
霍利斯特生物科學公司。(歐洲證券交易所股票代碼：HOL)(場外交易代碼：HSTRF)(法蘭克福股票代碼：HOB)宣佈財務業績星期一2021財年第三季度截至9月1日30.
The Vancouver-based company maintained a strong liquidity position over the period, including a cash and cash equivalents balance of $7.6 million, a 300% increase from the prior-year quarter.
這家總部位於温哥華的公司在此期間保持了強勁的流動性狀況，包括現金和現金等價物餘額為760萬美元，比去年同期增長300%。
CEO Jake Cohen said the company's performance is mainly attributable to the organic growth of its core business, Venom Extracts.
首席執行官傑克·科恩 説該公司的業績表現主要歸功於其核心業務--毒液提取物的有機增長。
"As we approach the end of our final quarter and the beginning of a period of transformation, our strengthened and experienced leadership team is laser-focused on creating shareholder value, delivering sustainable profitable growth, keeping operating costs low, and scaling the Company for optimal global success."
隨着我們接近最後一個季度末和轉型時期的開始，我們強大和經驗豐富的領導團隊專注於創造股東價值、實現可持續的盈利增長、保持較低的運營成本以及擴大公司規模，以獲得最佳的全球成功。“
Eula Adams, the company's CFO, continued, "Hollister's third-quarter results demonstrate the strength of our business and commitment to executing against our strategy. With its strong balance sheet, we believe the company is well-positioned and prepared for growth as it continues on its strategic transformation."
該公司首席財務官尤拉·亞當斯(Eula Adams)繼續説，霍利斯特公司第三季度的業績證明瞭我們業務的實力和執行我們戰略的承諾。憑藉其強勁的資產負債表，我們相信，隨着公司繼續進行戰略轉型，該公司已經做好了良好的定位，併為增長做好了準備。“
Q3 2021 Financial Highlights
2021年第三季度財務亮點
- Total revenue was $14.5 million, an increase of $5 million or 53% compared to the prior-year period.
- Gross profit was $3.5 million compared to $1.4 million for the prior-year period.
- Net income was $0.4 million versus a loss of $0.6 million in the prior-year period.
- Adjusted EBITDA was $1.2 million compared to a loss of $0.6 million in the prior-year period.
- 總收入為1450萬美元，與去年同期相比增加了500萬美元，增幅為53%。
- 毛利為350萬美元而去年同期為140萬美元。
- 淨收入為40萬美元而去年同期虧損60萬美元。
- 調整後的EBITDA為120萬美元而去年同期虧損60萬美元。
Q3 2021 And Recent Business Highlights
2021年第三季度和最近的業務亮點
In August, the company announced 'Hollister Brand Campus' a 30-Acre Arizona Brand Campus with a planned 700,000 square feet of cultivation area and an existing 28,500-square-foot processing and manufacturing facility.
8月份，該公司宣佈“霍利斯特品牌校園”佔地30英畝的亞利桑那州品牌校園計劃種植面積70萬平方英尺，現有28500平方英尺的加工和製造設施。
Shortly after, Hollister announced two new board members, including Kevin Harrington, an original "Shark" from the NBC hit TV series "Shark Tank," and Jakob Ripshtein, the former CFO of Diageo North America and president of Aphria Inc.
不久之後，霍利斯特宣佈了兩名新的董事會成員，其中包括美國全國廣播公司(NBC)熱門電視劇《鯊魚缸》(Shark Tank)中的原創人物凱文·哈林頓(Kevin Harrington)，以及雅各布·裏普什坦(Jakob Ripshtein)，前首席財務官帝亞吉歐北美和總裁Aphria Inc.
In October, Hollister appointed Jacob Cohen as CEO, Eula Adams as a CFO, Chris Lund as chief commercial officer and Jill Karpe as senior VP of admin and finance to create shareholder value, enhance governance, operations and market positioning while preparing the company for the next phase of its growth.
十月，霍利斯特任命雅各布·科恩為首席執行官，尤拉·亞當斯為首席財務官，克里斯·倫德為首席商務官，吉爾·卡普為行政和財務高級副總裁創造股東價值，加強治理、運營和市場定位，同時為公司下一階段的增長做好準備。
In November, the company's shareholders elected Jakob Ripshtein, Jacob Cohen, Eula Adams, Lily Dash, Kevin Harrington and Brett Mecum to serve as Hollister's directors.
11月，該公司的股東選舉雅各布·裏普什坦、雅各布·科恩、尤拉·亞當斯、莉莉·達什、凱文·哈林頓和佈雷特·梅庫姆擔任Hollister的董事。
HSTRF Price Action
HSTRF價格行動
Hollister Biosciences' shares traded 10.36% lower at $0.1515 per share at the time of writing Tuesday late morning.
霍利斯特生物科學公司股價下跌10.36%，至每股0.1515美元。在我寫這篇文章的時候，星期二上午晚些時候。
Photo: Courtesy of Chris Briggs on Unsplash
圖片：由克里斯·布里格斯在Unspash上提供
譯文內容由第三人軟體翻譯。